Principles of antipsychotic prescribing for policy makers, Circa 2008. Translating knowledge to promote individualized treatment

Schizophrenia Bulletin

Volumn 35, Issue 5, 2009, Pages 931-936

  Parks, Joseph ^a   Radke, Alan ^b   Parker, George ^c   Foti, May Ellen ^c   Eilers, Robert ^d   Diamond, Mary ^c   Svendsen, Dale ^e   Tandon, Rajiv ^f  

^a State of Missouri Department of Mental Health   (United States)

^b State of Minnesota Department of Mental Health   (United States)

^c State of Indiana Mental Health ^*  (United States)

^d State of New Jersey Health Services

^e Ohio Department of Mental Health   (United States)

^f State of Florida Mental Health Program Office   (United States)

Author keywords

Antipsychotic; Best practice; Cost effectiveness; Costs; Effectiveness; Policy; Schizophrenia; States; Treatment

Indexed keywords

NEUROLEPTIC AGENT;

COST EFFECTIVENESS ANALYSIS; HEALTH PROGRAM; HUMAN; KNOWLEDGE; MANAGEMENT; MEDICAL PRACTICE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; BENCHMARKING; COST-BENEFIT ANALYSIS; DRUG COSTS; FINANCING, GOVERNMENT; HEALTH EXPENDITURES; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES;

EID: 69249109145     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn019     Document Type: Review

References (36)

1. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;231:1371-1376.
2. Lieberman JA, Stroup ST, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
3. Jones PB, Davies L, Barnes TR, et al. Randomized controlled trial of effect on quality of life of second-generation versus first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry. 2006;63:1079-1087.
4. Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess (Rockv). 2006;10(17):1-182.
5. Swartz MS, Perkins DO, Stroup ST, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164:428-436.
6. Tandon R, Carpenter WT, Davis JM. First-and second-generation antipsychotics: learning from CUtLASS and CATIE. Arch Gen Psychiatry. 2007;64:977-978.
7. Kane JM, Leucht S, Carpenter D, Docherty JP. Expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry. 2003;64(suppl 12):1-100.
8. Tandon R, Belmaker RE, Gattaz W, et al. World Psychiatric Association Section on pharmacopsychiatry consensus statement on comparative antipsychotic effectiveness in schizophrenia. Schizophr Res. 2008;100:20-38.
9. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
10. Franciosi LP, Kasper S, Garber AJ, et al. Advancing the treatmentofpeoplewithmental illness:acall toactioninthemanagement ofmetabolic issues. J Clin Psychiatry. 2005;66:790-798.
11. American Psychiatric Association.Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(suppl 2):1-56.
12. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-508.
13. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
14. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176-184.
15. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry. 2002;51:972-978.
16. Erhart SM, Marder SR, Carpenter WT. Treatment of negative symptoms: future prospects. Schizophr Bull. 2006;32:234-237.
17. Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry. 2007; 64:633-647.
18. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
19. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158:518-526.
20. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophreniawho did not respond to prior antipsychotic treatment. Am J Psychiatry. 2006;163:600-610.
21. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32:715-723.
22. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185-194.
23. Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry. 2006;67:897-903.
24. Constantine RJ, Richard SM, Surles RC, et al. Optimizing pharmacotherapy of schizophrenia: tools for the psychiatrist. Curr Psychosis Ther Rep. 2006;4:5-11.
25. Tandon R, Targum SD, Nasrallah HA, Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Pract.12:348-363.
26. Marder SR, Essock SM, Miller AM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161:1334-1349.
27. Essock SM, Covell NH, Davis SM, Stroup SM, Rosenheck RA, Liberman JA. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163:2090-2095.
28. Davis JM, Marder SR, Tamminga CA. Switch or stay. Am J Psychiatry. 2006;163:2032-2033.
29. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611-622.
30. Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomized controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry. 2007;191:14-22.
31. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry. 2007;164:415-427.
32. Freedman R, Carpenter WT, Davis JM, Goldman HH, Tamminga CA, Thomas M. The costs of drugs for schizophrenia. Am J Psychiatry. 2006;163:2029-2031.
33. Hansen K, Lancon C, Toumi M. Pharmacoeconomic modeling in schizophrenia: trap or support for decision makers? Eur J Health Econ. 2006;7:19-29.
34. Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trialbased cost-effectiveness analyses of antipsychotic use. Am J Psychiatry. 2006;163:2047-2056.
35. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry. 2006;163:2080-2089.
36. Parks J, Radke A, Tandon R. Impact of CATIE on state mental health policy. Psychiatr Serv. 2008. In press.